CAR T-cell therapy in high-risk lymphoma

The 63rd American Society of Hematology (ASH) annual meeting saw a plethora of updates in lymphoma. While most of them generated a lot of fruitful conversations, some of the breakthroughs have the potential to change practice.

In this roundtable discussion, Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, and Wendy Osborne, MBBS (Hons), MRCP, FRCPath, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, review the most exciting updates in lymphoma from the 2021 ASH annual meeting and reflect on how the data may impact clinical practice in the UK.

The post The Lymphoma Sessions: post-ASH 2021 appeared first on VJHemOnc.